Granulomatosis with polyangiitis induced by the anti-programmed cell death-1 inhibitor tislelizumab:A case report  

作　　者：Jian-Hui Zhao Jing-Jiao Wang Yi-Wen Li 

机构地区：[1]Department of Nephrology,Xinchang County People's Hospital,Xinchang 312500,Zhejiang Province,China [2]Department of Medical Oncology,Xinchang County People's Hospital,Shaoxing 312500,Zhejiang Province,China [3]Department of Nephrology,Urology and Nephrology Center,Zhejiang Provincial People’s Hospital,Hangzhou 310014,Zhejiang Province,China

出　　处：《World Journal of Clinical Cases》2025年第15期56-62,共7页世界临床病例杂志(英文)

摘　　要：BACKGROUND Immune checkpoint inhibitors(ICIs)are a new class of antitumor agents.They enhance antitumor effects by blocking inhibitory receptors and related ligands expressed on T cells.ICIs also modulate regular immune cell activity,affecting the immune system and causing immune-related adverse events.The renal system is sometimes affected by these adverse events.Currently,the literature on ICIs-related glomerular injuries is scarce.CASE SUMMARY We present a patient who developed granulomatosis with polyangiitis(GPA)3 weeks after treatment with the anti-programmed cell death-1 inhibitor,tislel-izumab.The patient experienced proteinuria,hematuria,and acute kidney injury without pulmonary hemorrhage and tested positive for anti-neutrophil cyto-plasmic antibody(ANCA)-cytoplasmic type.Renal biopsy confirmed ANCA-associated vasculitis,and GPA was finally diagnosed.The patient received pulse treatment with glucocorticoids and cyclophosphamide,and renal function improved.After self-discontinuation of the drug,the disease recurred,and the original treatment regimen was continued.However,the patient’s renal function continued to deteriorate.CONCLUSION Glucocorticoids plus cyclophosphamide are effective for treating GPA induced by tislelizumab.However,follow-up and patient education are needed.

关 键 词：Tislelizumab Programmed cell death-1 inhibitor Granulomatosis with polyangiitis Anti-neutrophil cytoplasmic antibody-associated vasculitis Case report 

分 类 号：R69[医药卫生—泌尿科学]